The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable,

3 Biotech Stocks You Should Know About

02:35pm, Wednesday, 17'th Jul 2024
In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
Sarepta Therapeutics just received expanded labeling for one of its therapies. But the therapy has not performed as well as expected in clinical trials.
Previously, Sarepta's gene therapy treatment Elevidys was approved for only a limited number of Duchenne muscular dystrophy patients. Regulators, however, have expanded that range, and it can now be u

Best Momentum Stocks to Buy for July 3rd

11:00am, Wednesday, 03'rd Jul 2024
SRPT and ASYS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 3, 2024.
Sarepta Therapeutics' most important medicine now looks even more promising. The biotech's financial results are improving substantially.

New Strong Buy Stocks for July 3rd

07:50am, Wednesday, 03'rd Jul 2024
MONDY, MWA, SRPT, ASYS and CLCO have been added to the Zacks Rank #1 (Strong Buy) List on July 3, 2024.
Pfizer just whiffed one of its late-stage clinical trials. Sarepta Therapeutics just got regulators to sign off on a similar program.
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on Frid
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor
Sarepta Therapeutics excels in rare disease therapies using RNA, gene editing, and gene therapies, with significant revenue growth driven by ELEVIDYS gene therapy approval. Despite missing the primary
Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.
Ritu Baral, TD Cowen Sr. Biotechnology Analyst, joins 'Closing Bell Overtime' to talk Sarepta's approval from the FDA for its Duchenne gene therapy and how it drove the stock to its best trading day i
Click to get the best stock tips daily for free!

Top Fintech Company featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE